Here, we move toward the possible clinical application of CDH13 promoter methylation by 1) determining the appropriate methods for methylation detection and 2) evaluating clinical association with clinicopathological features of BC to determine the impact of methylation on clinical outcome. This evidence concerns the gene CDH13 and breast cancer.